نتائج البحث

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

• Authors : NRG Oncology

• Source: A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With

تفاصيل العنوان

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

• Source: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and

تفاصيل العنوان

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

• Authors : Anne Noonan, Principal Investigator

• Source: A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX

تفاصيل العنوان

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

• Source: A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction

تفاصيل العنوان

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

• Authors : ADIR, a Servier Group company

• Source: Phase I Dose-escalation of S 95005 (TAS-102) in Combination With Oxaliplatin in Metastatic Colorectal CancerBordonaro R, Calvo A, Auriemma A, Hollebecque A,

تفاصيل العنوان

PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer.

• Authors : Pei F; Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.; Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/adverse effects ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy Folfox protocol

• Source: Cancer medicine [Cancer Med] 2024 Jun; Vol. 13 (12), pp. e7224.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer

• Source: An Open-label, Multicenter, Single-arm, Phase 1b/2 Study of NANT-008 in Combination With 5-fluorouracil, Bevacizumab, Leucovorin, and

تفاصيل العنوان

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

• Authors : CSPC Ouyi Pharmaceutical Co., Ltd.; Tianshu Liu, Head of Medical oncology

• Source: Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line

تفاصيل العنوان

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

• Source: Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line

تفاصيل العنوان

Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.

• Authors : Moriwaki T; Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.; Gosho M

Subjects: Antimetabolites, Antineoplastic/Antimetabolites, Antineoplastic/Antimetabolites, Antineoplastic/*therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Bevacizumab/Bevacizumab/Bevacizumab/*therapeutic use

• Source: Cancer research and treatment [Cancer Res Treat] 2021 Jul; Vol. 53 (3), pp. 703-713. Date of Electronic Publication: 2020 Dec 01.Publisher: The Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان